RNAZ - TransCode Therapeutics Inc
IEX Last Trade
0.27
-0.009 -3.259%
Share volume: 194,599
Last Updated: Fri 30 Aug 2024 09:50:27 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.28
-0.01
-3.16%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-3.20%
1 Month
-2.44%
3 Months
-83.94%
6 Months
-62.45%
1 Year
-99.57%
2 Year
-99.97%
Key data
Stock price
$0.27
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.22 - $128.00
52 WEEK CHANGE
-$1.00
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website:
Employees: 16
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 16
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
transcode therapeutics is a boston based pre-clinical biopharmaceutical company focused on discovery, development and commercialization of a pipeline of innovative microrna (mirnas or mirs) therapeutics for treating metastatic disease.
Recent news